Headlines about Leap Therapeutics (NASDAQ:LPTX) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Leap Therapeutics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.0471678772032 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Leap Therapeutics (NASDAQ:LPTX) traded down $0.18 during trading on Wednesday, reaching $6.20. 59,700 shares of the company’s stock were exchanged, compared to its average volume of 30,485. Leap Therapeutics has a 52 week low of $4.90 and a 52 week high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Monday, November 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). equities research analysts anticipate that Leap Therapeutics will post -3.63 earnings per share for the current year.

Separately, Zacks Investment Research downgraded shares of Leap Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th.

In related news, COO Augustine Lawlor purchased 1,057,769 shares of the stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $6.09 per share, with a total value of $6,441,813.21. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-leap-therapeutics-lptx-stock-price.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.